Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02371616
Other study ID # 202199
Secondary ID
Status Completed
Phase N/A
First received February 19, 2015
Last updated March 9, 2018
Start date September 29, 2014
Est. completion date December 18, 2014

Study information

Verified date December 2017
Source GlaxoSmithKline
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

An 8 week clinical study to evaluate the ability of an experimental dentifrice containing calcium sodium phosphosilicate and sodium fluoride to provide relief from dentine hypersensitivity compared to a marketed dentifrice containing calcium sodium phosphosilicate and sodium monofluorophosphate.


Description:

A single centre, multi-site, randomised, examiner blind, two treatment, parallel group, non-inferiority design clinical study conducted in healthy subjects with self-reported and clinically diagnosed dentine hypersensitivity (DH). This study will compare the effectiveness of a test dentifrice containing 5% w/w calcium sodium phosphosilicate and fluoride as sodium fluoride to a commercially available dentifrice containing 5% w/w calcium sodium phosphosilicate and fluoride as sodium monofluorophosphate, in providing relief from DH after 4 and 8 weeks twice daily treatment.


Recruitment information / eligibility

Status Completed
Enrollment 304
Est. completion date December 18, 2014
Est. primary completion date December 18, 2014
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 60 Years
Eligibility Inclusion Criteria:

- subjects in good general health with no clinically significant/ relevant abnormalities of oral examination

- pre-existing self reported and clinically diagnosed tooth sensitivity

- at screening a minimum of 20 natural teeth and at least two accessible, non-adjacent teeth (incisors, canines or pre-molars) with signs of erosion or abrasion and/or facial/cervical gingival recession (EAR), with a Gingival Index =1 and clinical mobility =1, and with signs of DH as measured by qualifying evaporative (air) assessment

- at baseline, a minimum of 2 non-adjacent accessible teeth (incisors, canines or premolars) with DH (qualifying tactile threshold Yeaple = 20g, Schiff Sensitivity Score = 2)

Exclusion Criteria:

- subjects with a known or suspected intolerance or hypersensitivity to study products

- presence of chronic debilitating disease which could affect study outcomes

- any condition which is causing dry mouth

- use of an oral care product indicated for the relief of dentine hypersensitivity

- participation in a DH treatment study in the 8 weeks prior to screening

- taking daily doses of a medication/ treatment which could interfere with perception of pain or is causing dry mouth

- require antibiotic prophylaxis for dental procedures

- dental prophylaxis within 4 weeks of screening

- treatment of periodontal disease within 12 months of screening+C60

- scaling or root planing within 3 months of screening

- tooth bleaching within 8 weeks of screening

- active caries or periodontitis

- partial dentures, orthodontic appliances or dental implants which could affect study outcomes

- Pregnant and breast-feeding females

- Main Exclusions for Test Teeth: evidence of current or recent caries; treatment of decay within 12 months of screening; teeth with exposed dentine but with deep, defective or facial restorations; teeth used as abutments for fixed or removable partial dentures; teeth with full crowns or veneers, orthodontic bands or cracked enamel; sensitive teeth with contributing aetiologies other than erosion, abrasion or recession

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Calcium sodium phosphosilicate
5% w/w calcium sodium phosphosilicate
Other:
Sodium fluoride
1426 ppm fluoride as sodium fluoride
Sodium monofluorophosphate
1426 ppm fluoride as sodium monofluorophosphate

Locations

Country Name City State
United Kingdom GSK Investigational Site Ellesmere Port Cheshire
United Kingdom GSK Investigational Site Maldon Essex
United Kingdom GSK Investigational Site Wirral

Sponsors (1)

Lead Sponsor Collaborator
GlaxoSmithKline

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Mean Change From Baseline in Evaporative Air Sensitivity as Measured by Visual Analogue Score (VAS) at Week 8 Evaporative air sensitivity was assessed by examiner as a response to a 1 second application of air from a triple air dental syringe applied to the exposed dentine surface of hypersensitive tooth from a distance of approximately 1centimeter. Each participants rated the intensity of their response to the stimulus using a 100 millimeter (mm) VAS, were 0 represented "no pain" and 100 represented the" worst pain imaginable". Change from baseline was calculated as mean score at the given time point minus mean score at baseline of the two selected test teeth. At Baseline and Week 8
Secondary Mean Change From Baseline in Evaporative Air Sensitivity as Measured by Visual Analogue Score (VAS) at Week 4 Evaporative air sensitivity was assessed by examiner as a response to a 1 second application of air from a triple air dental syringe applied to the exposed dentine surface of hypersensitive tooth from a distance of approximately 1centimeter. Each participants rated the intensity of their response to the stimulus using a 100 mm VAS, were 0 represented "no pain" and 100 represented the" worst pain imaginable". Change from baseline was calculated as mean score at the given time point minus mean score at baseline of the two selected test teeth. At Baseline and Week 4
Secondary Mean Change From Baseline in Evaporative Air Sensitivity as Measured by Schiff Sensitivity Score at Week 4 and Week 8 Evaporative air sensitivity was measured by examiner as the participant's response to an evaporative air stimulus for each tooth using the Schiff Sensitivity Scale scored as follows - 0: Participant does not respond to air stimulation; 1: responds to air stimulus but does not request discontinuation of stimulus; 2: Participant responds to air stimulus and requests discontinuation or moves from stimulus; 3: Participant responds to stimulus, considers stimulus to be painful, and requests discontinuation of the stimulus. A reduction in Schiff Sensitivity score indicate improvement in sensitivity. Change from baseline was calculated as mean score at the given time point minus mean score at baseline of the two selected test teeth. At Baseline, Week 4 and Week 8
Secondary Change From Baseline in Tactile Threshold at Week 4 and Week 8 Tactile threshold was assessed by examiner using a constant pressure probe (Yeaple probe) which allowed application of a known force to the dentine surface from 10 g to an upper threshold of 80g in increments of 10 g. The tactile threshold is the maximum pressure applied at which participant do not report any pain or discomfort. The tactile threshold for each tooth was determined by asking the participant whether the sensation caused discomfort. The pressure setting at which the participant gave two consecutive 'yes' responses was recorded as the tactile threshold. The higher the tactile threshold, the less sensitive the tooth. Change from baseline was calculated as mean score at the given time point minus mean score at baseline of the two selected test teeth. At Baseline, Week 4 and Week 8
See also
  Status Clinical Trial Phase
Completed NCT02789618 - A Pilot Study to Substantiate the Use of the Jay Sensitivity Sensor Probe N/A